C. elegans Model for Early Alpha-Synuclein Neurodegeneration Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug discovery efforts for Parkinson's disease (PD) face challenges due to the lack of in vivo models that accurately recapitulate early stages of neurodegeneration, where treatments are most effective. Existing models either fail to capture early dopaminergic neuron degeneration or are not sensitive enough to indicate early stages of neurodegeneration.
Innovation Solution
The development of a C. elegans locomotor abnormality model that mimics early α-synuclein-mediated neurodegeneration, combined with an AI-driven in silico and in vitro drug repurposing screen, identifies therapeutics such as rifabutin, losartan, and abacavir as potential candidates for repurposing as disease-modifying therapies for PD and other α-synucleinopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing in vivo models are used, then the models can be established, but they fail to capture early stages of dopaminergic neuron degeneration
Solution Approach 1:
The patent creates a simplified C. elegans model that copies key features of early PD neurodegeneration without requiring complete replication of human disease complexity. The model expresses α-synuclein in dopaminergic neurons and uses locomotor abnormalities as a proxy marker for early neuronal dysfunction, enabling detection before significant cell loss occurs.
Solution Approach 2:
The patent employs fluorescent protein expression (color/fluorescence change) to visualize α-synuclein aggregation and dopaminergic neuron status in real-time. This allows direct observation of protein accumulation and neuronal integrity without requiring tissue sectioning or complex staining protocols.
2Reliability
If animal models with advanced neurodegeneration are used, then clear neurodegeneration is observable, but treatments are less effective because neuron loss is already extensive
Solution Approach 1:
The patent establishes the C. elongans model at an early stage where α-synuclein aggregation begins but before extensive neuronal loss occurs. This preliminary timing allows treatment intervention during the critical window when disease-modifying therapies can prevent or slow neurodegeneration, rather than addressing end-stage damage.
Solution Approach 2:
The patent replaces complex mammalian disease models with a simpler invertebrate system that exhibits comparable early neurodegenerative features. This substitution enables more sensitive detection of early stages and allows for rapid screening of potential treatments without the logistical complexities of mammalian models.
3Ease of manufacture
If traditional drug discovery approaches are used, then new compounds can be developed, but the process is time-consuming and lacks effective in vivo screening
Solution Approach 1:
The patent divides the drug discovery process into discrete, manageable stages: (1) in silico screening of compound libraries, (2) in vitro validation using cell-based α-synuclein aggregation assays, and (3) in vivo testing using C. elegans locomotor phenotype screens. This segmentation enables parallel processing and rapid iteration through multiple validation levels.
Solution Approach 2:
The C. elegans model serves multiple functions simultaneously: it provides an in vivo system for testing neuroprotective effects, enables high-throughput screening of compound libraries, allows real-time observation of neuronal dysfunction, and can be used to validate molecular mechanisms before mammalian model testing.
Data Source
AI summary
Provided is a method of treating a subject with an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, a method of treating a subject with a high risk of developing an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, wherein the one or more therapeutic(s) is or comprise rifabutin, one or more nucleoside analog reverse transcriptase inhibitor(s), optionally selected from lamivudine, emtricitabine, tenofovir disoproxil funiarate, tenofovir alafenamide, abacavir, zidovudine, didanosine, and/or stavudine, losartan, or a combination thereof.